We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Posts Biosimilars Q&A to Help Clarify Presubmission Meetings
EMA Posts Biosimilars Q&A to Help Clarify Presubmission Meetings
April 24, 2012
The European Medicines Agency (EMA) has published question-and-answer guidance on marketing applications for biosimilars, providing advice on a number of pre-submission issues, such as requesting an accelerated assessment, and giving detailed answers about review timing.